Compare BBDC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBDC | WVE |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.8M | 957.7M |
| IPO Year | 2006 | 2015 |
| Metric | BBDC | WVE |
|---|---|---|
| Price | $8.75 | $4.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $9.56 | ★ $29.81 |
| AVG Volume (30 Days) | 756.4K | ★ 3.1M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 11.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $85.67 |
| P/E Ratio | $16.87 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $7.97 | $4.56 |
| 52 Week High | $9.54 | $21.73 |
| Indicator | BBDC | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 34.14 |
| Support Level | $8.71 | N/A |
| Resistance Level | $9.41 | $6.33 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 9.47 | 10.53 |
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. It employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.